KR20200014880A - 테세탁셀 및 카페시타빈에 대한 투약 일정 - Google Patents

테세탁셀 및 카페시타빈에 대한 투약 일정 Download PDF

Info

Publication number
KR20200014880A
KR20200014880A KR1020207000023A KR20207000023A KR20200014880A KR 20200014880 A KR20200014880 A KR 20200014880A KR 1020207000023 A KR1020207000023 A KR 1020207000023A KR 20207000023 A KR20207000023 A KR 20207000023A KR 20200014880 A KR20200014880 A KR 20200014880A
Authority
KR
South Korea
Prior art keywords
capecitabine
day
administering
day cycle
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207000023A
Other languages
English (en)
Korean (ko)
Inventor
토마스 웨이
케빈 탕
스튜 크롤
존 지. 렘키
스티븐 파이퍼
제프 바치르카
Original Assignee
오더네이트 테라퓨틱스, 잉크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오더네이트 테라퓨틱스, 잉크. filed Critical 오더네이트 테라퓨틱스, 잉크.
Publication of KR20200014880A publication Critical patent/KR20200014880A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207000023A 2017-06-02 2018-06-01 테세탁셀 및 카페시타빈에 대한 투약 일정 Ceased KR20200014880A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762514483P 2017-06-02 2017-06-02
US62/514,483 2017-06-02
PCT/US2018/035653 WO2018223029A1 (en) 2017-06-02 2018-06-01 Dosing schedule for tesetaxel and capecitabine

Publications (1)

Publication Number Publication Date
KR20200014880A true KR20200014880A (ko) 2020-02-11

Family

ID=64455637

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207000023A Ceased KR20200014880A (ko) 2017-06-02 2018-06-01 테세탁셀 및 카페시타빈에 대한 투약 일정

Country Status (14)

Country Link
US (1) US20200179427A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630091A4 (cg-RX-API-DMAC7.html)
JP (1) JP2020522568A (cg-RX-API-DMAC7.html)
KR (1) KR20200014880A (cg-RX-API-DMAC7.html)
CN (1) CN111032035A (cg-RX-API-DMAC7.html)
AU (1) AU2018275122A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019025164A2 (cg-RX-API-DMAC7.html)
CA (1) CA3065783A1 (cg-RX-API-DMAC7.html)
EA (1) EA201992852A1 (cg-RX-API-DMAC7.html)
IL (1) IL270973A (cg-RX-API-DMAC7.html)
MA (1) MA50039A (cg-RX-API-DMAC7.html)
MX (1) MX2019014489A (cg-RX-API-DMAC7.html)
TW (1) TW201902473A (cg-RX-API-DMAC7.html)
WO (1) WO2018223029A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019359755A1 (en) * 2018-10-17 2021-05-20 Odonate Therapeutics, Inc. Methods of treating CNS tumors with tesetaxel
TW202112364A (zh) * 2019-08-16 2021-04-01 美商蜻蛉治療股份有限公司 投與替司他賽(tesetaxel)與cyp3a4誘導劑之糖皮質素之方法
WO2022177835A1 (en) * 2021-02-16 2022-08-25 Genentech, Inc. Treatment of breast cancer using combination therapies comprising gdc-9545 and ipatasertib

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201701880A (zh) * 2015-04-14 2017-01-16 莫瑞麥克製藥公司 改善持續釋放藥物治療之藥物動力學及治療指數之方法

Also Published As

Publication number Publication date
MA50039A (fr) 2020-07-08
JP2020522568A (ja) 2020-07-30
AU2018275122A1 (en) 2019-12-19
CA3065783A1 (en) 2018-12-06
MX2019014489A (es) 2020-08-17
EA201992852A1 (ru) 2020-03-27
BR112019025164A2 (pt) 2020-06-16
WO2018223029A1 (en) 2018-12-06
US20200179427A1 (en) 2020-06-11
CN111032035A (zh) 2020-04-17
TW201902473A (zh) 2019-01-16
EP3630091A1 (en) 2020-04-08
EP3630091A4 (en) 2021-03-10
IL270973A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
AU2013205648B2 (en) Combination treatment
US9370526B2 (en) Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
EA030335B1 (ru) Применение амисульприда в качестве противорвотного средства
US20220072011A1 (en) Treatments of accumulated fat with deoxycholic acid and salts thereof
EP4322942A1 (en) Combination comprising everolimus and amcenestrant
RU2010123028A (ru) Кортикостероиды для лечения диареи, индуцированной эпотилоном или производным эпотилона
CN102065865B (zh) 多发性骨髓瘤治疗
TW202304425A (zh) 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
TW202333675A (zh) 用於治療癌症之組合療法之用途
JP2010538066A5 (cg-RX-API-DMAC7.html)
US20260027088A1 (en) Inhibitors of Glutathione S-Transferases (GSTS) and NAD(P)H:Quinone Oxidoreductase 1 (NQO1), Pharmaceutical Compositions, and Uses in Managing Cancer
CN111032035A (zh) 用于替司他赛和卡培他滨的给药方案
ES2573295T3 (es) Combinaciones farmacéuticas que comprenden un inhibidor de Hsp90 derivado de isoxazol y el inhibidor de HER2 trastuzumab
WO2021034335A1 (en) Methods of administering tesetaxel with glucocorticoids that are cyp3a4 inducers
HK40029016A (en) Dosing schedule for tesetaxel and capecitabine
EP2485729A1 (en) Treatment with cholinergic agonists
CN102781238A (zh) Tivozanib和坦罗莫司的组合
WO2022197293A1 (en) Methods of administering tesetaxel to patients with hepatic impairment
AU2019359755A1 (en) Methods of treating CNS tumors with tesetaxel
WO2022197290A1 (en) Methods of administering tesetaxel with cyp3a4 inhibitors
US10098860B2 (en) Bezafibrate for the treatment of cancer
WO2026015820A1 (en) Methods of treating vexas
HK40123938A (en) Thyroid beta-agonist dosing regimens for the treatment of x-ald
IE20150193A1 (en) Kinetin (N6-Furfuryadenine) for preventing and treating mucositis and proctitis and erythemia
WO2026085172A1 (en) Combination therapy for treating hematological cancers

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210527

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230309

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230529

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230309

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I